Neovasc Inc. (NASDAQ:NVCN)

CAPS Rating: No stars 0.00

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

5 Outperform
4 Underperform
 

All-Star Players

2 Outperform
4 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NVCN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Bigsef77 (68.53)
Submitted January 29, 2019

Neovasc Receives Approval to Proceed with Phase 2 of TIARA-II Study from Clinical Regulators in Germany and the UK[CNW Group]CNW Group•January 29, 2019Successfully completed all Phase 1 requirements of TIARA-IINASDAQ, TSX: NVCNVANCOUVER , Jan 29,… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NVCN VS S&P 500 (SPY)

NVCN Summary

Recent Community Commentary

Read the most recent pitches from players about NVCN.

Recs

1
Member Avatar Bigsef77 (68.53) Submitted: 1/29/2019 10:56:38 AM : Outperform Start Price: $3.11 NVCN Score: -82.13

Neovasc Receives Approval to Proceed with Phase 2 of TIARA-II Study from Clinical Regulators in Germany and the UK
[CNW Group]
CNW Group•January 29, 2019

Successfully completed all Phase 1 requirements of TIARA-II

NASDAQ, TSX: NVCN

VANCOUVER , Jan 29, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it has completed the Phase 1 requirements of the TIARA-II study required by the bi-phasic study design in both Germany and the United Kingdom and has received approval to proceed with Phase 2 of the TIARA-II study for its Tiara™ transcatheter mitral valve replacement device (the "Tiara"). This approval comes following Clinical Events Committee adjudication of adverse events, Data and Safety Monitoring Board review of the data, and Governmental regulatory and ethics committees reviews of the interim clinical report provided for 20 implanted subjects. This approval will allow the TIARA-II study to proceed in these geographies with no restrictions.

The TIARA-II study is an international, multicenter, single-arm, prospective, non-randomized, safety and performance clinical study. The total enrollment goal for the study in all geographies is 115 implanted subjects.

"The Neovasc team is excited about the positive news from the governmental healthcare authorities in Germany and the UK, as well as from the independent ethics committees in both countries. After their review of the submitted, detailed results of the first 20 Tiara implants, we received all required approvals to continue this TIARA-II clinical study into the second and final phase of full enrollment, without further restrictions," commented Fred Colen , Neovasc's President and Chief Executive Officer.

Leaderboard

Find the members with the highest scoring picks in NVCN.

Score Leader

ClientNein

ClientNein (99.98) Score: +176.33

The Score Leader is the player with the highest score across all their picks in NVCN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
wolfhounds 91.74 9/24/2018 Underperform 5Y $3.05 -86.49% -4.06% +82.42 0 Comment
IWantToBeatBabo 99.92 9/28/2018 12/18/2018 Underperform NS $2.82 -85.38% -3.70% +81.68 0 Comment
ClientNein 99.98 1/17/2019 Underperform 5Y $0.78 -47.07% +7.02% +54.09 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. gpierson128 98.09 1/14/2019 Underperform 5Y $0.62 -32.96% +8.72% +41.68 0 Comment
Maddentycoon 33.22 2/15/2019 Outperform 3W $0.68 -39.72% +1.05% -40.77 0 Comment
PAGEBOY54 95.64 1/23/2019 Outperform 1Y $0.77 -46.46% +6.28% -52.75 0 Comment
PAGEBOY73 99.05 1/24/2019 Outperform 1Y $0.78 -47.14% +6.09% -53.24 0 Comment
Bigsef77 68.53 10/3/2018 Outperform 3Y $3.11 -86.74% -4.61% -82.13 1 Comment
tstapez22 41.99 10/23/2018 Outperform 5Y $2.28 -81.92% +3.06% -84.98 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NVCN.

Advertisement